Czech Republic Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Czech Republic Pharmaceuticals and Healthcare Report

Czech Republic Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Czech Republic Pharmaceuticals and Healthcare Report
Published Aug 06, 2016
79 pages — Published Aug 06, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

Still increasing level of per-capita expenditure with continued steady long-term potential. The Czech Republic has considerable biotechnology potential, with well-established clinical research and an EU-aligned regulatory infrastructure. The OTC sector s growth potential remains considerable as self-treatment of minor ailments continues and there are proposals to liberalise OTC sales. The Czech branded medicines market should grow thanks to demand for innovative treatments, although values will be challenged by pricing and reimbursement regimes. A skilled workforce, stable business environment and sound government incentives to attract foreign investment. ...The Czech branded medicines market should grow thanks to demand for innovative treatments, although values will be challenged by pricing and reimbursement regimes. A skilled workforce, stable business environment and sound government incentives to attract foreign investment.

...In Q- ----, the Czech Republic s BMI Risk/Reward Index (RRI) score has been upgraded slightly from the previous quarter to --.- out of ---. Within our RRI matrix, the Czech Republic is ranked as the most attractive market in the Central and Eastern European (CEE) region to innovative drugmakers. ...In Q- ----, the Czech Republic s BMI Risk/Reward Index (RRI) score has been upgraded slightly from the previous quarter to --.- out of ---. Within our RRI matrix, the Czech Republic is ranked as the most attractive market in the Central and Eastern European (CEE) region to innovative drugmakers. The Czech pharmaceutical market score is driven by high pharmaceutical expenditure per capita, an ageing population and a favourable urban-rural distribution, but dragged down by a challenging pricing and reimbursement environment. ...Within our RRI matrix, the Czech Republic is ranked as the most attractive market in the Central and Eastern European (CEE) region to innovative drugmakers. The Czech pharmaceutical market score is driven by high pharmaceutical expenditure per capita, an ageing population and a favourable urban-rural distribution, but dragged down by a challenging pricing and reimbursement environment.

...Prescribing budgets and the requirement that certain products only be prescribed by specialists restrict the marketplace for patented medicines. Budgetary problems and delayed health reforms could provoke industrial action among restive healthcare workers, after recent strikes by doctors. ...

  
Source:
Document ID
1748-1856
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Czech Republic Pharmaceuticals and Healthcare Report" Aug 06, 2016. Alacra Store. Dec 06, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Czech-Republic-Pharmaceuticals-and-Healthcare-Report-2026-285>
  
APA:
Business Monitor International - Industry Reports. (2016). Czech Republic Pharmaceuticals and Healthcare Report Aug 06, 2016. New York, NY: Alacra Store. Retrieved Dec 06, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Czech-Republic-Pharmaceuticals-and-Healthcare-Report-2026-285>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.